Research graph
References from BRAF-altered glioma in adults and children: A Society for Neuro-Oncology and European Association of Neuro-Oncology consensus review on clinical management and future directions. Local targets link to admitted publications; unresolved targets remain external evidence.
Mutations of the BRAF gene in human cancer
10.1038/nature00766 · 2002 · External reference
BRAF: a tumour-agnostic drug target with lineage-specific dependencies
10.1038/s41571-023-00852-0 · 2024 · External reference
BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition
10.1016/j.ccell.2015.08.001 · 2015 · External reference
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
10.1038/nature23291 · 2017 · External reference
Integrated molecular and clinical analysis of BRAF-mutant glioma in adults
10.1038/s41698-023-00359-y · 2023 · External reference
Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas
10.1016/j.ccell.2020.03.011 · 2020 · External reference
Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma
10.1016/j.ccell.2017.08.017 · 2017 · External reference
Genomic correlates of disease progression and treatment response in prospectively characterized gliomas
10.1158/1078-0432.ccr-19-0032 · 2019 · External reference
Biology and grading of pleomorphic xanthoastrocytoma: what have we learned about it?
10.1111/bpa.12874 · 2021 · External reference
The genetic landscape of anaplastic pleomorphic xanthoastrocytoma
10.1111/bpa.12639 · 2019 · External reference
Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases
10.1111/bpa.12103 · 2014 · External reference
The genetic landscape of ganglioglioma
10.1186/s40478-018-0551-z · 2018 · External reference
Intramedullary gangliogliomas: histopathologic and molecular features of 25 cases
10.1016/j.humpath.2015.09.041 · 2016 · External reference
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
10.1093/neuonc/noad008 · 2023 · External reference
BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas
10.1002/jso.23822 · 2015 · External reference
Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology
10.1007/s00401-016-1539-z · 2016 · External reference
Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis
10.1111/bpa.12566 · 2018 · External reference
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway
10.1007/s00401-016-1639-9 · 2017 · External reference
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations
10.1007/s00401-018-1837-8 · 2018 · External reference
A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation
10.1007/s00401-023-02651-4 · 2023 · External reference
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
10.1007/s00401-011-0841-z · 2011 · External reference
Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry
10.1097/pas.0000000000000325 · 2015 · External reference
Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data
10.1111/nan.12683 · 2021 · External reference
Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
10.1016/j.ccell.2025.11.002 · 2026 · External reference
Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: an analysis of 469 tumors
10.1093/noajnl/vdaf089 · 2025 · External reference
Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features
10.1007/s10014-021-00407-0 · 2021 · External reference
BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation
10.1097/pas.0000000000000363 · 2015 · External reference
Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma
10.1007/s11060-021-03719-5 · 2021 · External reference
Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type
10.1007/s00234-019-02304-y · 2020 · External reference
MR imaging of pediatric low-grade gliomas: pretherapeutic differentiation of BRAF V600E mutation, BRAF fusion, and wild-type tumors in patients without neurofibromatosis-1
10.3174/ajnr.a7574 · 2022 · External reference
An emerging pediatric CNS tumor: imaging evaluation of H3K27M and BRAF V600E comutated midline tumors
10.3174/ajnr.a9006 · 2026 · External reference
Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations 2004
10.1111/j.1468-1331.2004.00867.x · 2004 · External reference
The 2021 WHO classification of tumors of the central nervous system: a summary
10.1093/neuonc/noab106 · 2021 · External reference
Pediatric low-grade gliomas
10.1177/0883073809342005 · 2009 · External reference
Eans\u2011eano guidelines on the extent of resection in gliomas
10.1093/neuonc/noaf217 · 2026 · External reference
Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis
10.1007/s11060-022-04176-4 · 2022 · External reference
A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children’s Oncology Group
10.1007/s11060-018-2983-5 · 2018 · External reference
A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702)
10.1093/neuonc/noq092 · 2010 · External reference
Response assessment in pediatric neuro-oncology: implementation and expansion of the RANO criteria in a randomized phase II trial of pediatric patients with newly diagnosed high-grade gliomas
10.3174/ajnr.a4782 · 2016 · External reference
Phase II trial of conformal radiation therapy for pediatric low-grade glioma
10.1200/jco.2008.20.9494 · 2009 · External reference
Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits
10.1200/jco.2008.21.2738 · 2009 · External reference
Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis
10.1093/neuonc/noaa031 · 2020 · External reference
Neurocognitive outcomes in pediatric brain tumors after treatment with proton versus photon radiation: a systematic review and meta-analysis
10.1007/s12519-023-00726-6 · 2023 · External reference
Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood
10.1200/jco.1993.11.5.850 · 1993 · External reference
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group
10.1200/jco.2011.36.6054 · 2012 · External reference
Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma
10.1200/jco.2011.34.5843 · 2012 · External reference
Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study
10.1200/jco.2016.68.1585 · 2016 · External reference
Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations
10.1056/nejmoa2303815 · 2023 · External reference
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
10.1093/neuonc/nou059 · 2014 · External reference
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4
10.1093/neuonc/noaf065 · 2025 · External reference
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
10.1038/s41591-023-02668-y · 2024 · External reference
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: a modified Delphi approach to build international consensus-based definitions—international pediatric low-grade glioma coalition
10.1093/neuonc/noae074 · 2024 · External reference
Canadian consensus for treatment of BRAF V600E mutated pediatric and AYA gliomas
10.3390/curroncol31070299 · 2024 · External reference
Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma
10.1200/jco.21.02929 · 2023 · External reference
Long-term follow-up of pediatric benign cerebellar astrocytomas
10.1227/neu.0b013e31822ff0ed · 2012 · External reference
Extent of resection, MGMT promoter methylation status and tumor location independently predict progression-free survival in adult sporadic pilocytic astrocytoma
10.3390/cancers11081072 · 2019 · External reference
Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance)
10.1093/nop/npv031 · 2015 · External reference
Upfront observation versus radiation for adult pilocytic astrocytoma
10.1002/cncr.25988 · 2011 · External reference
Low-grade gangliogliomas in adults: a population-based study
10.1002/cam4.3577 · 2021 · External reference
Chemotherapy in adult patients with pilocytic astrocytoma: a retrospective multicenter cohort study
10.1007/s11060-025-05275-8 · 2025 · External reference
A national perspective of adult gangliogliomas
10.1016/j.jocn.2015.12.028 · 2016 · External reference
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
10.1016/s1470-2045(21)00578-7 · 2022 · External reference
BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study
10.1200/jco.2018.78.9990 · 2018 · External reference
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
10.1038/s41591-023-02321-8 · 2023 · External reference
Clinical, histological and molecular features of gliomas in adults with neurofibromatosis type 1
10.1093/neuonc/noad033 · 2023 · External reference
MEK inhibition with trametinib is a successful therapy in ganglioglioma
10.15761/ccrr.1000479 · 2020 · External reference
MEK inhibition in a pilocytic astrocytoma with a rare KRAS Q61R mutation in a young adult patient: a case report
10.1200/po.24.00174 · 2024 · External reference
ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma
10.1016/j.radonc.2024.110594 · 2025 · External reference
No drug holidays in BRAF(V600E) glioma patients: an argument for dose reduction of targeted therapies
10.1093/nop/npae046 · 2024 · External reference
Rebound growth following temporary discontinuation of BRAFi and MEKi in a patient with multifocal BRAFV600E-mutant primary brain tumor
10.1212/wnl.0000000000213336 · 2025 · External reference
Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines
10.1007/s11060-024-04672-9 · 2024 · External reference
CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021
10.1093/neuonc/noaf168 · 2025 · External reference
Extent of tumor resection and survival in pediatric patients with high-grade gliomas: a systematic review and meta-analysis
10.1001/jamanetworkopen.2022.26551 · 2022 · External reference
Sex, age, anatomic location, and extent of resection influence outcomes in children with high-grade glioma
10.1227/neu.0000000000000845 · 2015 · External reference
High-grade gliomas in children and adolescents: is there a role for reoperation?
10.3171/2020.7.peds20389 · 2021 · External reference
Unresolved reference
2026 · External reference
Phase II trial of dabrafenib plus trametinib in relapsed/refractory BRAF V600-mutant pediatric high-grade glioma
10.1200/jco.23.00558 · 2023 · External reference
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma
10.1093/neuonc/noac096 · 2022 · External reference
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial: a report from the Childrens Cancer Study Group
10.1007/bf00165101 · 1989 · External reference
Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen: Childrens Cancer Group
10.1200/jco.1995.13.1.112 · 1995 · External reference
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group
10.1093/neuonc/noq191 · 2011 · External reference
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the children’s oncology group ACNS0423 study
10.1093/neuonc/now038 · 2016 · External reference
Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
10.18632/oncotarget.26560 · 2019 · External reference
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas
10.1002/pbc.24891 · 2014 · External reference
Pilomyxoid astrocytoma treated successfully with vemurafenib
10.1002/pbc.25084 · 2014 · External reference
Sustained response to targeted therapy in a patient with disseminated anaplastic pleomorphic xanthoastrocytoma
10.1097/mph.0000000000001032 · 2018 · External reference
Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab
10.1002/pbc.27465 · 2019 · External reference
Dabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: results from a phase 1/2a single-arm study
10.1093/nop/npaf061 · 2025 · External reference
Successful treatment of pediatric patients with high-grade gliomas featuring leptomeningeal metastases by targeting BRAF V600E mutations with dabrafenib plus trametinib: two illustrative cases
10.1007/s13691-024-00674-6 · 2024 · External reference
Successful treatment with dabrafenib/trametinib of a malignantly transformed and metastasized BRAF V600E mutant pleiomorphic xanthoastrocytoma: a case report and review of the literature
10.1159/000534731 · 2024 · External reference
H3K27M- and BRAF V600E-altered gliomas and glioneuronal tumors-clinico-pathologic and radiologic perspective in a cohort treated with targeted therapy
10.1093/noajnl/vdaf197 · 2025 · External reference
Challenging the odds: long-term survival in pediatric diffuse midline glioma with H3 K27M and BRAF V600 co-mutations treated with upfront radiotherapy and targeted therapy
10.1002/pbc.31929 · 2025 · External reference
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1
10.1007/s00401-022-02478-5 · 2022 · External reference
Prevalence of BRAFV600 in glioma and use of BRAF inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
10.1093/neuonc/noab247 · 2022 · External reference
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-update 1
10.1093/neuonc/noae213 · 2025 · External reference
Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis
10.1016/j.ejca.2023.112959 · 2023 · External reference
Glioblastoma in adults: a society for neuro-oncology (SNO) and european society of neuro-oncology (EANO) consensus review on current management and future directions
10.1093/neuonc/noaf177 · 2025 · External reference
Clinicopathological, immunohistochemical and therapeutic approaches on survival in patients with epithelioid glioblastoma: Institutional experience in the management of 58 patients
10.1007/s10143-024-02957-1 · 2024 · External reference
Clinical and molecular predictors of survival and treatment response in AYA/adults with BRAF-V600 mutant high-grade glioma
10.1093/neuonc/noaf201.1029 · 2025 · External reference
Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma
10.1158/1078-0432.ccr-23-3241 · 2024 · External reference
A critical review of RAF inhibitors in BRAF-mutated glioma treatment
10.1080/14622416.2024.2355859 · 2024 · External reference
Clinical experience with tovorafenib in adults with treatment-refractory high- and low-grade gliomas
2025 · External reference
Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
10.1002/cam4.1267 · 2018 · External reference
Systemic therapy for oligoprogression in patients with metastatic NSCLC harboring activating EGFR mutations
10.3390/cancers14030832 · 2022 · External reference
MGMT gene silencing and benefit from temozolomide in glioblastoma
10.1056/nejmoa043331 · 2005 · External reference
Unresolved reference
2025 · External reference
Tumor adaptation and resistance to RAF inhibitors
10.1038/nm.3392 · 2013 · External reference
Fertility preservation in people with cancer: ASCO guideline update
10.1200/jco-24-02782 · 2025 · External reference
Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines†
10.1016/j.annonc.2020.09.006 · 2020 · External reference
Unresolved reference
2014 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2024 · External reference
BRAF and MEK inhibitors and their toxicities: a meta-analysis
10.3390/cancers15010141 · 2022 · External reference
RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events
10.1093/nop/npaa006 · 2020 · External reference
Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)
10.18632/oncotarget.27600 · 2020 · External reference
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study
10.1016/s0140-6736(25)00986-9 · 2025 · External reference
Lgg-40. TYPE II Raf inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (PLGG): reversible decreases in growth velocity in the phase 2 firefly-1 trial
2024 · External reference
Trls-02. SAFETY and efficacy of BRAF inhibitor plixorafenib (fore8394; plx8394) in children and adults with recurrent, BRAF-altered primary central nervous system tumors (PCNST)
10.1093/neuonc/noae064.155 · 2024 · External reference
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
10.1038/s41591-020-1060-8 · 2020 · External reference
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
10.1038/s41467-021-26572-6 · 2021 · External reference
Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG)
10.1016/j.ijrobp.2016.01.038 · 2016 · External reference
Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance
10.1007/s10147-024-02479-2 · 2024 · External reference
Deconvoluting mechanisms of acquired resistance to RAF inhibitors in BRAF(V600E)-mutant human glioma
10.1158/1078-0432.ccr-21-2660 · 2021 · External reference
Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas
10.18632/oncotarget.11882 · 2017 · External reference
Adaptive resistance to dual BRAF/MEK inhibition in BRAF-driven tumors through autocrine FGFR pathway activation
10.1158/1078-0432.ccr-18-2779 · 2019 · External reference
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model
10.18632/oncotarget.12419 · 2016 · External reference
Regulation of TORC1 by MAPK signaling determines sensitivity and acquired resistance to trametinib in pediatric BRAFV600E brain tumor models
10.1158/1078-0432.ccr-22-1052 · 2022 · External reference
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma
10.1200/jco.2014.58.3922 · 2015 · External reference
Co-occurring genomic alterations and association with progression-free survival in BRAFV600-mutated nonmelanoma tumors
10.1093/jnci/djx094 · 2017 · External reference
Targeting a Plk1-controlled polarity checkpoint in therapy-resistant glioblastoma-propagating cells
10.1158/0008-5472.can-14-3689 · 2015 · External reference
BRAF V600E in a preclinical model of pleomorphic xanthoastrocytoma: analysis of the tumor microenvironment and immune cell infiltration dynamics in vivo
10.1016/j.omton.2024.200808 · 2024 · External reference
Multi-pronged analysis of pediatric low-grade glioma reveals a unique tumor microenvironment associated with BRAF alterations
10.1101/2024.04.05.588294 · 2024 · External reference
BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAF(V600E)-mutant glioma
10.1016/j.xcrm.2025.102183 · 2025 · External reference
Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma
10.1093/noajnl/vdaf170 · 2025 · External reference
Abstract 3248: circulating tumor DNA analysis of patients with BRAF-mutated advanced unresectable solid tumors treated with plixorafenib (FORE8394/PLX8394) in phase 1/2a study
10.1158/1538-7445.am2025-3248 · 2025 · External reference
Prolonged complete response with combined dabrafenib and trametinib after BRAF inhibitor failure in BRAF-Mutant glioblastoma
10.1200/po.19.00272 · 2020 · External reference
CTNI-76. Efficacy of BRAF inhibitor plixorafenib (FORE8394) in recurrent primary CNS tumors
10.1093/neuonc/noad179.0358 · 2023 · External reference
Unresolved reference
2024 · External reference
Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors
10.7554/elife.19671 · 2017 · External reference
HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E-mutant high-grade glioma
10.1158/1078-0432.ccr-21-3622 · 2022 · External reference
Combined immunotherapy improves outcome for replication-repair-deficient (RRD) high-grade glioma failing anti-PD-1 monotherapy: a report from the International RRD Consortium
10.1158/2159-8290.cd-23-0559 · 2024 · External reference
Update on the DREAMseq trial in melanoma
2023 · External reference
Systemic therapy for melanoma: ASCO guideline update Q and A
10.1200/op.23.00675 · 2024 · External reference
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma
10.1007/s11060-015-1939-2 · 2016 · External reference
MEK inhibition enhances the antitumor effect of radiotherapy in NF1-deficient glioblastoma
10.1158/1535-7163.mct-23-0510 · 2024 · External reference
Use of single-arm trials for US Food and Drug Administration drug approval in oncology, 2002-2021
10.1001/jamaoncol.2022.5985 · 2023 · External reference
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial
10.1038/s41591-025-03928-9 · 2025 · External reference
Leveraging external data in the design and analysis of clinical trials in neuro-oncology
10.1016/s1470-2045(21)00488-5 · 2021 · External reference
External control arms in oncology: current use and future directions
10.1016/j.annonc.2021.12.015 · 2022 · External reference
Use of external control cohorts in pediatric brain tumor clinical trials
10.1200/jco.23.01084 · 2024 · External reference
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
10.1016/j.ejca.2025.115230 · 2025 · External reference
